Browse
 
Dahl Chase Folders

NRAS Mutation Assay (12, 13, and 61)

Reference Number: AA-00431

SECTION EIGHT

Dahl-Chase Diagnostic Services

MOLECULAR PATHOLOGY TESTING

NRAS MUTATION ASSAY

Clinical Significance:

NRAS is a protein that plays a central role in the growth and survival of cancer cells and is mutated in a number of different tumors.  NRAS is integral in the RAS/RAF/MEK/ERK/MAPK pathway, which is involved in the transduction of mitogenic signals from the cell membrane to the nucleus.  The NRAS gene is located on the short arm of chromosome 12 (12p12).  Testing for RAS family mutations in colon cancer patients is now a standard of patient care.  The National Comprehensive Cancer Network (NCCN) guidelines (v1.2015) recommends determining the mutational status of KRAS exon 2 (codons 12 and 13), KRAS non-exon2 (codon 61 and 146), and NRAS exon 2 (codon 12 and 13) and NRAS non-exon 2 (codon 61) in patients with colorectal adenocarcinoma. 

 

Specimen Requirements and Collection:

Formalin fixed tissue containing a sufficient amount of tumor (generally at least several mm of tumor tissue submitted in the tissue block). 

 

Forms:

Molecular Pathology requisition form

 

Transport:

Send paraffin block containing tumor at room temperature

 

Reference Range:

NRAS mutation not detected = negative result

NRAS mutation detected = positive result

 

 

CPT codes:

 

88381, 81404, G0452

 

 

Test reported:

Results are reported within 7-10 days